Date de publication: 10 juillet 2019
Promoteur – Intermédiaire Financier
PAION AGLieu
Description
The promoter is a pharmaceutical company developing a novel short-acting anaesthetic compound. The eligible investment plan includes research and development (R&D) and related expenses to finance the development and regulatory filing of the drug, including the costs associated with a paediatric formulation of the product.
Objectifs
The proposed transaction will support R&D investments required to advance the promoter's product pipeline and bring the products to market.
Secteur(s)
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 20 million
Coût total (montant approximatif)
EUR 69 million
Aspects environnementaux
The promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Passation des marchés
The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Statut
Signé - 28/06/2019
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).